open access

Vol 61, No 4 (2010)
Original papers
Published online: 2010-08-31
Submitted: 2013-02-15
Get Citation

The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods

Piotr Glinicki, Renata Kapuścińska, Wojciech Jeske
Endokrynologia Polska 2010;61(4):346-350.

open access

Vol 61, No 4 (2010)
Original papers
Published online: 2010-08-31
Submitted: 2013-02-15

Abstract


Introduction: Chromogranin A (CgA) is regarded as a major, nonspecific marker of neuroendocrine tumors (NET). Its estimation appears helpful for diagnostic purposes and is particularly useful for monitoring the treatment of NET. It must be kept in mind, however, that various factors, drugs, or coexisting diseases may influence the outcome of CgA measurement in blood. One such analytical factor is the sort of studied biological material, whether it is plasma or serum. The aim of our study was to compare directly the results of CgA concentrations measured in serum and in plasma by IRMA and ELISA.
Material and methods: We analysed 122 samples of EDTA-plasma and 122 samples of serum by IRMA method, 20 samples of EDTAplasma and 20 samples of serum by IRMA and ELISA, 25 heparinised-plasma samples and 25 samples of EDTA-plasma by IRMA and ELISA methods, and 8 EDTA-plasma, heparinised-plasma, and serum samples by IRMA and ELISA. The material for comparative study was obtained during the same blood collection from the same subjects (volunteers and patients with NET). CgA was measured with the use of kits manufactured by CIS bio International (France).
Results: CgA concentrations were markedly higher in plasma than in serum. Using the IRMA method, the difference in the CgA range between 10-100 ng/mL approached 20-70% (median 61 v. 42), in the range 101-300 ng/mL - 12-60% (median 147 v. 101), and in the CgA range 301-1076 ng/mL - 14-40% (median 486 v. 356). The differences between results in serum and plasma using ELISA were similar but slightly smaller. There was no significant difference between CgA levels in EDTA and heparinised-plasma samples, and the results of measurements performed by IRMA and ELISA in most cases were similar.
Conclusions: Referring each individual CgA result to the proposed reference range (or cut-off value) we must take into account whether the measurement is performed in plasma or in serum. (Pol J Endocrinol 2010; 61 (4): 346-350)

Abstract


Introduction: Chromogranin A (CgA) is regarded as a major, nonspecific marker of neuroendocrine tumors (NET). Its estimation appears helpful for diagnostic purposes and is particularly useful for monitoring the treatment of NET. It must be kept in mind, however, that various factors, drugs, or coexisting diseases may influence the outcome of CgA measurement in blood. One such analytical factor is the sort of studied biological material, whether it is plasma or serum. The aim of our study was to compare directly the results of CgA concentrations measured in serum and in plasma by IRMA and ELISA.
Material and methods: We analysed 122 samples of EDTA-plasma and 122 samples of serum by IRMA method, 20 samples of EDTAplasma and 20 samples of serum by IRMA and ELISA, 25 heparinised-plasma samples and 25 samples of EDTA-plasma by IRMA and ELISA methods, and 8 EDTA-plasma, heparinised-plasma, and serum samples by IRMA and ELISA. The material for comparative study was obtained during the same blood collection from the same subjects (volunteers and patients with NET). CgA was measured with the use of kits manufactured by CIS bio International (France).
Results: CgA concentrations were markedly higher in plasma than in serum. Using the IRMA method, the difference in the CgA range between 10-100 ng/mL approached 20-70% (median 61 v. 42), in the range 101-300 ng/mL - 12-60% (median 147 v. 101), and in the CgA range 301-1076 ng/mL - 14-40% (median 486 v. 356). The differences between results in serum and plasma using ELISA were similar but slightly smaller. There was no significant difference between CgA levels in EDTA and heparinised-plasma samples, and the results of measurements performed by IRMA and ELISA in most cases were similar.
Conclusions: Referring each individual CgA result to the proposed reference range (or cut-off value) we must take into account whether the measurement is performed in plasma or in serum. (Pol J Endocrinol 2010; 61 (4): 346-350)
Get Citation

Keywords

chromogranin A; CgA; CgA-IRMA; CgA-ELISA; neuroendocrine tumours

About this article
Title

The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods

Journal

Endokrynologia Polska

Issue

Vol 61, No 4 (2010)

Pages

346-350

Published online

2010-08-31

Bibliographic record

Endokrynologia Polska 2010;61(4):346-350.

Keywords

chromogranin A
CgA
CgA-IRMA
CgA-ELISA
neuroendocrine tumours

Authors

Piotr Glinicki
Renata Kapuścińska
Wojciech Jeske

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl